EC approves Pfizer’s Bavencio plus axitinib to treat advanced RCC

This article was originally published here

Bavencio, which is a human anti-programmed death ligand-1 (PD-L1) antibody, has been demonstrated in preclinical models to engage both the adaptive and innate immune functions. The combined therapy

The post EC approves Pfizer’s Bavencio plus axitinib to treat advanced RCC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply